Sponsors should consider continuing translational science in parallel with their pivotal clinical trials, particularly if they may want to rely on that science as confirmatory evidence to meet the US Food and Drug Administration’s effectiveness standard, Peter Stein, FDA’s Center for Drug Evaluation and Research Office of New Drugs director, said.
Stein raised the issue due to concerns that a lack of this research is
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?